Name: NEUPHORIA THERAPEUTICS INC (NEUP) Stock
Brand: NEUPHORIA THERAPEUTICS INC
Rating: 3.5 (3 reviews)

NEUP Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

19 days ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

a month ago - By: Stocktwits - Mentions: PSIL VXF

NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition

a month ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

2 months ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

2 months ago - By: Stocktwits

Why Did NEUP Stock Surge 64% Today?

a year ago - By: Benzinga - Mentions: BAOS SPRC SVRE LAES ...

Dow Gains 50 Points, SEALSQ Shares Plummet

2 months ago - By: Benzinga - Mentions: PMI GNTA AVR USBC ...

12 Health Care Stocks Moving In Friday's Intraday Session

2 months ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

2 months ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

3 months ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

4 months ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

7 months ago - By: Neuphoria Therapeutics, Inc.

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

7 months ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Provides First Quarter 2025 Business Updates

9 months ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

10 months ago - By: Stocktwits - Mentions: MRK

Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes

10 months ago - By: Neuphoria Therapeutics, Inc.

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

a year ago - By: Neuphoria Therapeutics, Inc.

NEUPHORIA THERAPEUTICS INC (NEUP) Stock News

NEUP Latest News, Press Relases and Analysis

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

Why Did NEUP Stock Surge 64% Today?

Dow Gains 50 Points, SEALSQ Shares Plummet

12 Health Care Stocks Moving In Friday's Intraday Session

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Neuphoria Provides First Quarter 2025 Business Updates

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq